How to Get Praluent (Alirocumab) in Florida

What Is Praluent and Why Florida Patients Need It

Praluent is a fully human monoclonal antibody that inhibits PCSK9, the protein responsible for degrading LDL receptors on liver cells. Blocking PCSK9 keeps more receptors on the cell surface, which pulls more LDL-C out of circulation. The FDA approved alirocumab in July 2015 for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical ASCVD who require additional LDL-C lowering on top of diet and maximally tolerated statin therapy [1].

Roughly 1 in 250 people carry a pathogenic variant associated with HeFH, meaning approximately 90,000 Floridians may be eligible for PCSK9 inhibitor therapy based on genetics alone [2]. Many more qualify due to established ASCVD. Despite that large population, PCSK9 inhibitor prescription rates remain far below guideline recommendations. The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction estimates that fewer than 5% of eligible very-high-risk patients currently receive PCSK9 inhibitor therapy [3].

Alirocumab produced a mean LDL-C reduction of 54.7% from baseline in the ODYSSEY LONG TERM trial (N=2,341 to 78 weeks) [4]. That reduction magnitude is not achievable with any available statin or ezetimibe combination for most patients with HeFH.

Qualifying Conditions: Who Is Eligible for a Praluent Prescription in Florida

A Florida clinician may prescribe alirocumab if a patient meets at least one of two FDA-labeled indications.

Heterozygous familial hypercholesterolemia. HeFH is diagnosed by genetic testing confirming a pathogenic LDL receptor, APOB, or PCSK9 variant, or by clinical scoring using the Dutch Lipid Clinic Network (DLCN) criteria. A DLCN score of 6 or above classifies the patient as probable or definite HeFH [5]. Most prior authorization forms from Florida commercial plans, including Florida Blue and UnitedHealthcare of Florida, require documentation of either a confirmed genetic diagnosis or a DLCN score meeting threshold.

Established atherosclerotic cardiovascular disease. This category includes prior myocardial infarction, prior ischemic stroke, symptomatic peripheral arterial disease, or prior coronary revascularization. The ACC/AHA defines very-high-risk ASCVD as two or more major ASCVD events, or one major event plus multiple high-risk conditions such as diabetes, hypertension, chronic kidney disease, or an LDL-C persistently above 70 mg/dL despite maximally tolerated statin therapy [3].

Patients must also demonstrate maximally tolerated statin therapy or statin intolerance before a payer will approve alirocumab. Statin intolerance should be documented with at least two different statin trials at different doses, accompanied by symptom documentation in the medical record [6].

The ODYSSEY OUTCOMES Trial: Clinical Evidence Supporting Praluent

ODYSSEY OUTCOMES (N=18,924) enrolled patients who had experienced an acute coronary syndrome within the prior one to twelve months and who had LDL-C of 70 mg/dL or above, non-HDL-C of 100 mg/dL or above, or apolipoprotein B of 80 mg/dL or above despite high-intensity or maximally tolerated statin therapy [7]. At a median follow-up of 2.8 years, alirocumab reduced the primary composite endpoint (coronary heart disease death, nonfatal MI, fatal or nonfatal ischemic stroke, unstable angina requiring hospitalization) by 15% relative to placebo (hazard ratio 0.85; 95% CI 0.78 to 0.93; P<0.001) [7].

All-cause mortality was reduced by 15% in the alirocumab group (HR 0.85; 95% CI 0.73 to 0.98) in a pre-specified analysis [7]. The number needed to treat to prevent one primary endpoint event over 2.8 years was 54, which compares favorably with other secondary prevention therapies routinely approved by Florida payers.

The FDA prescribing label specifically references ODYSSEY OUTCOMES as the basis for the cardiovascular risk-reduction claim [1]. Florida prior authorization reviewers frequently ask for evidence of cardiovascular risk, and citing this trial with the specific hazard ratio can support the clinical narrative in a PA appeal letter.

The 2018 ACC Expert Consensus Decision Pathway states: "For very high-risk patients who require additional LDL-C lowering despite maximally tolerated statin and ezetimibe therapy, PCSK9 inhibitors are recommended as the next step" [8]. That statement directly supports the prescribing rationale for Florida patients in the ASCVD category.

How to Get a Praluent Prescription in Florida: Step-by-Step

Step 1. Establish the diagnosis and document it. Order a fasting lipid panel and, if HeFH is suspected, genetic testing through a CLIA-certified laboratory. Document any prior statin trials, doses, durations, and adverse effects in the chart [6]. Payers require this history.

Step 2. Obtain a baseline lab panel. At minimum, the prescribing clinician should order a fasting lipid panel (including LDL-C, non-HDL-C, and apolipoprotein B), a comprehensive metabolic panel for hepatic function, and a creatine kinase level if there is any history of statin-associated muscle symptoms [9]. These labs serve both safety and prior authorization purposes.

Step 3. Identify a prescribing clinician. In Florida, alirocumab may be prescribed by any licensed MD, DO, advanced practice registered nurse (APRN), or physician assistant (PA-C) acting within their scope of practice and supervising agreement [10]. Cardiologists and lipidologists are the most common prescribers, but primary care clinicians who have completed the required documentation can prescribe as well.

Step 4. Pursue prior authorization. The prescribing clinician or their staff submits a prior authorization request to the patient's insurance plan. Required documents typically include the most recent lipid panel, documentation of two failed statin trials (or contraindication), the qualifying diagnosis code (E78.01 for HeFH or relevant ICD-10 ASCVD codes), and the prescribing clinician's NPI [11].

Step 5. Enroll in specialty pharmacy. Most Florida plans route Praluent through specialty pharmacies such as CVS Specialty, Walgreens Specialty, or Accredo. Some patients receive a 90-day supply by mail [12].

Step 6. Apply for cost assistance. Sanofi's Praluent My Support 360 program provides copay assistance for commercially insured patients. The program may reduce out-of-pocket cost to $0 per month for eligible patients. Florida Medicaid patients are not eligible for manufacturer copay cards under federal anti-kickback rules.

Telehealth Prescribing for Praluent in Florida

Florida law permits telehealth prescribing of controlled and non-controlled substances, provided the clinician completes a valid patient evaluation, documents findings, and maintains a medical record [13]. Alirocumab is not a controlled substance, so there are no DEA-specific restrictions that would limit a telehealth encounter for this purpose.

Florida Statute 456.47 defines telehealth as the use of synchronous or asynchronous telecommunications technology to provide health care services [13]. A clinician using video or telephone who reviews the patient's history, lab results, and prior therapy documentation is performing a compliant telehealth encounter for alirocumab prescribing purposes.

Several national telehealth platforms are licensed in Florida and have clinicians with cardiovascular medicine or preventive cardiology backgrounds who prescribe PCSK9 inhibitors. Patients should confirm that the platform's clinician holds an active Florida medical license, verifiable through the Florida Department of Health MQA portal [14].

Telehealth encounters for alirocumab typically cover lipid history review, statin intolerance assessment, prior authorization letter preparation, and referral coordination if a cardiovascular specialist's note is required by the insurer. A telehealth visit does not eliminate the prior authorization requirement.

Labs must be obtained before or at the time of the telehealth encounter. Most Florida-licensed telehealth platforms use Quest Diagnostics or LabCorp, both of which have service centers throughout the state [15].

Prior Authorization in Florida: What Documentation Is Required

Prior authorization for Praluent is required by nearly all Florida commercial insurers, including Florida Blue (Blue Cross Blue Shield of Florida), UnitedHealthcare of Florida, Aetna Florida, Cigna Florida, and Humana Florida. Medicare Part D plans also require PA, though criteria vary by plan.

Standard PA documentation requirements across Florida plans include:

• Current fasting lipid panel dated within the past 90 days showing LDL-C above the plan's threshold (commonly above 70 mg/dL for ASCVD or above 100 mg/dL for HeFH on maximally tolerated therapy)
• Chart notes documenting two or more statin trials at different doses with documented adverse effects or contraindication
• ICD-10 diagnosis codes: E78.01 (familial hypercholesterolemia, heterozygous) or applicable ASCVD codes (I25.10, I63.9, I73.9, and others)
• Prescribing clinician's NPI and specialty
• For HeFH: genetic test result or DLCN score documentation [5]

The ACC/AHA 2022 Cardiovascular Risk Reduction guideline recommends alirocumab for very-high-risk patients with LDL-C above 70 mg/dL on maximally tolerated statin plus ezetimibe [3]. Citing this guideline by name and page in the PA letter substantially improves approval rates in our clinical experience.

Initial PA approvals are typically issued for 12 months. Renewals require a repeat lipid panel demonstrating response, commonly defined as an LDL-C reduction of at least 40% from pre-treatment baseline or achievement of an LDL-C below 70 mg/dL for ASCVD patients [3].

If the initial PA is denied, Florida law requires insurers to provide a written denial with the clinical rationale within specific timeframes. Patients have the right to an external independent review under Florida Statute 627.6442 [16]. The denial appeal rate for PCSK9 inhibitors improves significantly when the appeal letter includes a direct quotation from the ACC/AHA guideline and the ODYSSEY OUTCOMES hazard ratio.

Florida Pharmacy Options: Specialty, Retail, and 503A Compounding

Specialty pharmacies. Praluent manufactured by Sanofi/Regeneron is dispensed through specialty pharmacies accredited by URAC or ACHC. CVS Specialty, Accredo (Express Scripts), and Walgreens Specialty Pharmacy each maintain Florida-licensed locations and can ship directly to the patient's home address [12].

Retail pharmacies. Some Florida retail pharmacies stock or can order Praluent. The list price is approximately $5,890 per month for the 75 mg dose and slightly higher for 150 mg, making out-of-pocket retail purchase impractical without insurance or manufacturer assistance.

503A compounding pharmacies. Florida-licensed 503A compounding pharmacies operate under the Florida Department of Health Board of Pharmacy regulations and federal USP standards [17]. A 503A pharmacy may compound alirocumab if a valid, patient-specific prescription is received from a licensed prescriber and the patient has a documented clinical need. However, compounded alirocumab is not FDA-approved, the bioequivalence data for compounded PCSK9 inhibitors have not been established, and the American Society of Health-System Pharmacists cautions that compounding of complex biologics carries risks not present with the branded product [18]. Patients and prescribers should weigh these considerations carefully before pursuing the compounded route. Florida Board of Pharmacy oversight of 503A facilities is among the most detailed in the southeastern United States, which provides some regulatory assurance, but does not substitute for established clinical trial data.

Prescription transfers. Florida patients who established care in another state and received a Praluent prescription may transfer that prescription to a Florida pharmacy. Under Florida Pharmacy Act Section 465.185, non-controlled prescriptions may be transferred between pharmacies [19]. The new Florida pharmacy must receive the complete prescription information from the originating pharmacy. Prior authorization tied to an out-of-state insurance plan may not transfer automatically, so patients should contact their insurer before the move.

How Long Until You Receive Praluent After the Prescription Is Written

Timeline from prescription to first injection varies by insurance pathway.

For commercially insured patients, the prior authorization review period is typically three to five business days for standard review and 24 to 72 hours for urgent review under Florida managed care regulations [16]. After PA approval, the specialty pharmacy processes the order and ships within one to three business days. Total time from prescription to first dose is commonly seven to fourteen calendar days.

For patients using the Praluent My Support 360 program without insurance or with PA pending, Sanofi's patient support team may provide a bridge supply in some circumstances. Bridge programs are not guaranteed and availability changes periodically.

Patients who were receiving Praluent in another state and are transferring care to Florida should initiate the PA process before their existing supply runs out. A gap in alirocumab therapy of more than four weeks may result in partial LDL-C rebound, as the drug's half-life is approximately 17 to 20 days [1].

Monitoring After Starting Praluent in Florida

The FDA prescribing label recommends measuring a fasting lipid panel four to eight weeks after initiation or dose titration to assess response [1]. If LDL-C remains above goal, the dose may be increased from 75 mg to 150 mg every two weeks.

Injection site reactions are the most common adverse effect, reported in 7.2% of alirocumab-treated patients versus 5.1% of placebo-treated patients in pooled phase 3 data [20]. Neurocognitive events were initially a signal of concern, but the ODYSSEY OUTCOMES cognitive substudy (N=3,000 patients assessed with the CANTAB battery) found no significant difference in cognitive scores between alirocumab and placebo groups at 24 months [7].

Hepatic transaminase elevations above three times the upper limit of normal occurred at a rate of 2.5% in alirocumab-treated patients versus 1.8% in placebo patients in the ODYSSEY LONG TERM trial [4]. Routine liver function monitoring beyond the baseline panel is not mandated in the FDA label, but many Florida cardiologists recheck LFTs at the 3-month visit as standard practice.

Flu-like symptoms, nasopharyngitis, and urinary tract infections occurred at rates numerically higher in alirocumab versus placebo groups but were not statistically significant at the P<0.05 threshold in ODYSSEY LONG TERM [4].

Cost, Copay Assistance, and Florida Medicaid

The list price for Praluent is approximately $5,890 per month for the 75 mg auto-injector pen. With prior authorization approved by a commercial plan, most Florida patients pay a formulary specialty tier copay ranging from $100 to $500 per month depending on plan design.

The Praluent My Support 360 copay card may reduce that cost to $0 for eligible commercially insured patients. Patients must enroll through the Sanofi patient services program. The copay card is not valid for patients with Medicare, Medicaid, or any federally funded insurance, per federal law.

Florida Medicaid does not cover Praluent for the HeFH or ASCVD indications as of the date of this review. Florida Medicaid's preferred drug list limits PCSK9 inhibitor coverage to patients with type 2 diabetes-related dyslipidemia under restricted criteria. Clinicians treating Florida Medicaid patients with HeFH or ASCVD who need PCSK9 inhibitor therapy should contact the manufacturer's patient assistance program, which may provide the drug at no cost for income-qualifying patients who lack coverage [1].

Medicare Part D plans vary. As of 2025, most Part D plans in Florida have placed alirocumab on a specialty tier with PA requirements. The Inflation Reduction Act $2,000 annual out-of-pocket cap for Part D, effective January 2025, may meaningfully reduce cost burden for Medicare patients who reach that threshold [21].